Results 31 to 40 of about 80,955 (206)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

Journal for ImmunoTherapy of Cancer, 2021
Background Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions.
Dorota Wyczechowska, Amir A Al-Khami, Luis Del Valle, Augusto C Ochoa, Mohamed A Ghonim, Salome V Ibba, Abdelmetalab F Tarhuni, Youssef Errami, Hanh H Luu, Matthew J Dean, Ali H El-Bahrawy, Ilyes A Benslimane, A Hamid Boulares   +12 more
doaj   +1 more source

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells [PDF]

, 2017
Mutations in homologous recombination (HR) genes BRCA1 and BRCA2 predispose to tumorigenesis. HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire resistance and relapse. Mechanistic understanding how
Rottenberg, Sven, Gogola, Ewa, Bouwman, P, Gogola, E, Sohvi Blatter, van Vugt, Marcel A T M, van Vugt, MATM, van Vugt, Marcel A. T. M., Anne Margriet Heijink, Madalena Tarsounas, Foijer, Floris; id_orcid, Blatter, S, Foijer, Floris, Foijer, F, Peter Bouwman, Bouwman, Peter, Stok, Colin, Jos Jonkers, Schoonen, Pepijn M, Floris Foijer, Blatter, Sohvi, Talens, F, Jonkers, J, Schoonen, PM, Colin Stok, Marcel A. T. M. van Vugt, Heijink, Anne Margriet, Sven Rottenberg, Tarsounas, M, Pepijn M. Schoonen, van Vugt, Marcel A. T. M.; id_orcid, Jonkers, Jos, Francien Talens, Stok, C, Blatter, Sohvi Tuulikki, Tarsounas, Madalena, Schoonen, Pepijn M., Talens, Francien, Rottenberg, S, Heijink, AM, Ewa Gogola   +40 more
core   +1 more source

The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment [PDF]

, 2020
International audiencePoly(ADP-ribose) polymerase (PARP) inhibitors are used in the treatment of BRCA-deficient cancers, with treatments currently extending toward other homologous recombination defective tumors.
Chapuis, Catherine, Timinszky, Gyula, Mamar, Hasan, Huet, Sébastien, Zentout, Siham, Schauer, Tamás, Spekhardt, Dóra, Juhász, Szilvia, Smith, Rebecca   +8 more
core   +1 more source

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer

Cells, 2020
The role and therapeutic promise of poly-ADP ribose polymerase (PARP) inhibitors in anticancer chemotherapy are increasingly being explored, particularly in adjuvant or maintenance therapy, considering their low efficacy as monotherapy agents and their ...
Shiue-Wei Lai, Oluwaseun Adebayo Bamodu, Jia-Hong Chen, Alexander TH Wu, Wei-Hwa Lee, Tsu-Yi Chao, Chi-Tai Yeh   +6 more
doaj   +1 more source

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Journal of Experimental & Clinical Cancer Research, 2018
Background Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy.
Xiaoting Lin, Dongshao Chen, Cheng Zhang, Xiaotian Zhang, Zhongwu Li, Bin Dong, Jing Gao, Lin Shen   +7 more
doaj   +1 more source

Role of akt activation in PARP inhibitor resistance in cancer

, 2020
Poly(ADP-ribose) polymerase (PARP) inhibitors have recently been introduced in the therapy of several types of cancers not responding to conventional treatments.
Szabo, Csaba, Gallyas, Ferenc, Sumegi, Balazs   +2 more
core   +2 more sources

PARP Inhibitors in Ovarian Cancer [PDF]

Recent Patents on Anti-Cancer Drug Discovery, 2018
Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical ...
Gloria, Mittica, Eleonora, Ghisoni, Gaia, Giannone, Sofia, Genta, Massimo, Aglietta, Anna, Sapino, Giorgio, Valabrega   +6 more
openaire   +2 more sources

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

Haematologica, 2009
Background Aberrant or impaired repair of double-strand DNA breaks is a common feature of de novo acute myeloid leukemia and myelodysplastic syndromes.
Terry J. Gaymes, Sydney Shall, Lee J. MacPherson, Natalie A. Twine, Nicholas C. Lea, Farzin Farzaneh, Ghulam J. Mufti   +6 more
doaj   +1 more source

Reverse the Resistance to PARP Inhibitors [PDF]

International Journal of Biological Sciences, 2017
One of the DNA repair machineries is activated by Poly (ADP-ribose) Polymerase (PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single-strand DNA, thus decreasing the chances of generating double-strand breaks in the genome.
Kim, Yevgeniy, Kim, Aleksei, Sharip, Ainur, Sharip, Aigul, Jiang, Juhong, Yang, Qing, Xie, Yingqiu   +6 more
openaire   +2 more sources

Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

EMBO Molecular Medicine, 2012
PARP inhibitors have been proposed as a potential targeted therapy for patients with triple‐negative (ER‐, PR‐, HER2‐negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be ...
Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord, Alan Ashworth   +6 more
doaj   +1 more source